Sorbinil

Sorbinil
Structural formula of sorbinil
Ball-and-stick model of the sorbinil molecule
Names
Preferred IUPAC name
(4S)-6-Fluoro-2,3-dihydrospiro[[1]benzopyran-4,4′-imidazolidine]-2,5-dione
Other names
(S)-6-Fluorospiro(chroman-4,4'-imidazolidine)-2',5'-dione; CP 45634
Identifiers
CAS Number
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.210.173
Edit this at Wikidata
KEGG
PubChem CID
UNII
InChI
  • InChI=1S/C11H9FN2O3/c12-6-1-2-8-7(5-6)11(3-4-17-8)9(15)13-10(16)14-11/h1-2,5H,3-4H2,(H2,13,14,15,16)/t11-/m0/s1
SMILES
  • Fc3ccc2OCC[C@@]1(C(=O)NC(=O)N1)c2c3
Properties[1]
Chemical formula
 C11H9FN2O3
Molar mass 236.202 g·mol−1
Appearance White to off-white powder
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Sorbinil (INN) is an aldose reductase inhibitor being investigated for treatment of diabetic complications including neuropathy and retinopathy.[3] Aldose reductase is an enzyme present in lens and brain that removes excess glucose by converting it to sorbitol. Sorbitol accumulation can lead to the development of cataracts in the lens and neuropathy in peripheral nerves. Sorbinil has been shown to inhibit aldose reductase in human brain[4] and placenta[5] and calf[6] and rat lens.[5] Sorbinil reduced sorbitol accumulation in rat lens and sciatic nerve of diabetic rats orally administered 0.25 mg/kg sorbinil.[5]

References

  1. ↑ Sorbinil at Sigma-Aldrich
  2. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names (Rec. INN): List 25" (PDF). World Health Organization. 1985. Retrieved 11 November 2016.
  3. ↑ MacCari, R; Del Corso, A; Giglio, M; Moschini, R; Mura, U; Ottanà, R (2011). "In vitro evaluation of 5-arylidene-2-thioxo-4-thiazolidinones active as aldose reductase inhibitors". Bioorganic & Medicinal Chemistry Letters. 21 (1): 200–3. doi:10.1016/j.bmcl.2010.11.041. PMID 21129963.
  4. ↑ O'Brien MM; et al. (1982). "Inhibition of human brain aldose reductase and hexonate dehydrogenase by alrestatin and sorbinil". J Neurochem. 39: 810–4. doi:10.1111/j.1471-4159.1982.tb07964.x. PMID 6808090.
  5. 1 2 3 Kinoshita JH; et al. (1979). "Aldose reductase in diabetic complications of the eye". Metabolism. 28 (suppl 1): 462–9. doi:10.1016/0026-0495(79)90057-x. PMID 45423.
  6. ↑ Peterson MJ; et al. (1979). "CP45,634: A novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats". Metabolism. 28 (Suppl 1): 456–61. doi:10.1016/0026-0495(79)90056-8. PMID 122297.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.